451 related articles for article (PubMed ID: 25117777)
1. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis.
Arias MT; Vande Casteele N; Vermeire S; de Buck van Overstraeten A; Billiet T; Baert F; Wolthuis A; Van Assche G; Noman M; Hoffman I; D'Hoore A; Gils A; Rutgeerts P; Ferrante M
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):531-8. PubMed ID: 25117777
[TBL] [Abstract][Full Text] [Related]
2. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
Turner D; Griffiths AM; Veerman G; Johanns J; Damaraju L; Blank M; Hyams J
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1460-5. PubMed ID: 23672831
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with short- and long-term outcomes of therapy for Crohn's disease.
Reinisch W; Colombel JF; Sandborn WJ; Mantzaris GJ; Kornbluth A; Adedokun OJ; Miller M; Tang KL; Rutgeerts P; Cornillie F
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):539-547.e2. PubMed ID: 25245629
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
[TBL] [Abstract][Full Text] [Related]
5. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience.
Laharie D; Filippi J; Roblin X; Nancey S; Chevaux JB; Hébuterne X; Flourié B; Capdepont M; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2013 May; 37(10):998-1004. PubMed ID: 23521659
[TBL] [Abstract][Full Text] [Related]
6. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
[TBL] [Abstract][Full Text] [Related]
7. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
[TBL] [Abstract][Full Text] [Related]
8. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Nardone OM; De Vitis I; Papa A; Rapaccini GL; Guidi L
Inflamm Bowel Dis; 2014 Aug; 20(8):1368-74. PubMed ID: 24983979
[TBL] [Abstract][Full Text] [Related]
9. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
10. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy.
Monterubbianesi R; Aratari A; Armuzzi A; Daperno M; Biancone L; Cappello M; Annese V; Riegler G; Orlando A; Viscido A; Meucci G; Gasbarrini A; Guidi L; Lavagna A; Sostegni R; Onali S; Papi C; Kohn A;
J Crohns Colitis; 2014 Aug; 8(8):852-8. PubMed ID: 24472490
[TBL] [Abstract][Full Text] [Related]
11. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis.
Gibson DJ; Heetun ZS; Redmond CE; Nanda KS; Keegan D; Byrne K; Mulcahy HE; Cullen G; Doherty GA
Clin Gastroenterol Hepatol; 2015 Feb; 13(2):330-335.e1. PubMed ID: 25086187
[TBL] [Abstract][Full Text] [Related]
12. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.
Magnusson MK; Strid H; Isaksson S; Bajor A; Lasson A; Ung KA; Öhman L
J Crohns Colitis; 2015 Jan; 9(1):56-65. PubMed ID: 25518051
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
Jakobovits SL; Jewell DP; Travis SP
Aliment Pharmacol Ther; 2007 May; 25(9):1055-60. PubMed ID: 17439506
[TBL] [Abstract][Full Text] [Related]
14. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.
Baert F; Drobne D; Gils A; Vande Casteele N; Hauenstein S; Singh S; Lockton S; Rutgeerts P; Vermeire S
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1474-81.e2; quiz e91. PubMed ID: 24486408
[TBL] [Abstract][Full Text] [Related]
15. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
[TBL] [Abstract][Full Text] [Related]
16. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
[TBL] [Abstract][Full Text] [Related]
17. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study.
Mocciaro F; Renna S; Orlando A; Rizzuto G; Sinagra E; Orlando E; Cottone M
J Crohns Colitis; 2012 Jul; 6(6):681-6. PubMed ID: 22398101
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.
Papamichael K; Vande Casteele N; Gils A; Tops S; Hauenstein S; Singh S; Princen F; Van Assche G; Rutgeerts P; Vermeire S; Ferrante M
Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1103-10. PubMed ID: 25478919
[TBL] [Abstract][Full Text] [Related]
20. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.
Kohn A; Daperno M; Armuzzi A; Cappello M; Biancone L; Orlando A; Viscido A; Annese V; Riegler G; Meucci G; Marrollo M; Sostegni R; Gasbarrini A; Peralta S; Prantera C
Aliment Pharmacol Ther; 2007 Sep; 26(5):747-56. PubMed ID: 17697208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
